Article citationsMore>>
Yamada, S., Kawakami, T., Nakatsugawa, Y., Suzuki, T., Fujii, H., Tomatsuri, N., Nakamura, H., Sato, H., Okuyama, Y., Kimura, H. and Yoshida, N. (2016) Usefulness of Vonoprazan, a Potassium Ion-Competitive Acid Blocker, for Primary Eradication of Helicobacter pylori. World Journal of Gastrointestinal Pharmacology and Therapeutics, 7, 550-555.
https://doi.org/10.4292/wjgpt.v7.i4.550
has been cited by the following article:
-
TITLE:
Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for Helicobacter pylori
AUTHORS:
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki
KEYWORDS:
Vonoprazan, Eradication, Helicobacter pylori, Propensity Score Matching, Gastric Mucosal Atrophy
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.7 No.9,
September
28,
2017
ABSTRACT: Aim: To investigate the factors related to the effect of eradication therapy with vonoprazan for Helicobacter pylori (H. pylori). Methods: We retrospectively reviewed medical records of H. pylori-positive patients who received first-line (40 mg vonoprazan/60 mg lansoprazole or 20 mg rabeprazole, 1500 mg amoxicillin, 400 mg clarithromycin, all 2/day for 7 days) (n = 4118). H. pylori eradication was assessed by the 13C-urea breath test with success defined as a result of H. pylori eradication therapy using vonoprazan was more effective than standard triple therapy with proton pump inhibitor. Gastric mucosal atrophy was associated with treatment success.
Related Articles:
-
Esra Ertan
-
Vincenzo Manca
-
Yasser Abu-Safieh, Hanin Yamin
-
Hikaru Endo, Kentaro Suehiro, Junji Kinoshita, Yukio Agatsuma
-
Huu S. Tieu, Martin F. Loeffler, Edgar A. Ayala